 | Up a level |
Haddad, Robert; Guigay, Joel; Keilholz, Ulrich; Clement, Paul M; Fayette, Jérôme; de Souza Viana, Luciano; Rolland, Frédéric; Cupissol, Didier; Geoffrois, Lionnel; Kornek, Gabriela; Licitra, Lisa; Melichar, Bohuslav; Ribaldo Nicolau, Ulisses; Rauch, Daniel; Zanetta-Devauges, Sylvie; Cohen, Ezra E W; Machiels, Jean-Pascal; Tahara, Makoto; Vermorken, Jan; Geng, Yuan; ... (2019). Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial. Oral oncology, 97, pp. 82-91. Elsevier 10.1016/j.oraloncology.2019.08.004
Sherman, Steven I; Wirth, Lori J; Droz, Jean-Pierre; Hofmann, Michael; Bastholt, Lars; Martins, Renato G; Licitra, Lisa; Eschenberg, Michael J; Sun, Yu-Nien; Juan, Todd; Stepan, Daniel E; Schlumberger, Martin J (2008). Motesanib diphosphate in progressive differentiated thyroid cancer. New England journal of medicine NEJM, 359(1), pp. 31-42. Waltham, Mass.: Massachusetts Medical Society MMS 10.1056/NEJMoa075853
